Literature DB >> 7426749

Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.

J Chediak, J B Ashenhurst, I Garlick, R K Desser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7426749

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  Acquired factor V inhibitors: a systematic review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-05       Impact factor: 2.300

2.  Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency.

Authors:  Beth A Bouchard; John Chapin; Kathleen E Brummel-Ziedins; Peter Durda; Nigel S Key; Paula B Tracy
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

Review 3.  Immunologically generated circulating anticoagulants in humans.

Authors:  R L Edwards; C J Wakem
Journal:  Surv Immunol Res       Date:  1984

4.  Laparoscopic hepatectomy for hepatocellular carcinoma in a patient with congenital factor V deficiency: a case report.

Authors:  Takaomi Seki; Mariko Tsukagoshi; Norifumi Harimoto; Kenichiro Araki; Akira Watanabe; Norihiro Ishii; Kei Hagiwara; Kouki Hoshino; Ryo Muranushi; Satoru Kakizaki; Yoshiyuki Ogawa; Hiroshi Handa; Ken Shirabe
Journal:  Surg Case Rep       Date:  2022-10-22

5.  Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

Authors:  T L Ortel; M A Quinn-Allen; L A Charles; D Devore-Carter; W H Kane
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

6.  Isolation and study of an acquired inhibitor of human coagulation factor V.

Authors:  M E Nesheim; W L Nichols; T L Cole; J G Houston; R B Schenk; K G Mann; E J Bowie
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

7.  Rapid elimination of a high-titer spontaneous factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression.

Authors:  B Tribl; P Knöbl; K Derfler; S Kapiotis; G Aspöck; U Jäger; W Hörl; K Lechner
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

8.  Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease.

Authors:  Eisuke Katsuren; Kentaro Kohagura; Takanori Kinjyo; Ryo Zamami; Takuto Nakamura; Nanako Oshiro; Yoshitsugu Sunagawa; Kumiko Omine; Yuki Kudo; Yuki Shinzato; Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose; Masanobu Yamazato; Akio Ishida; Yusuke Ohya
Journal:  CEN Case Rep       Date:  2022-08-09

9.  A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.

Authors:  Yasuko Kadohira; Shinya Yamada; Tomoe Hayashi; Eriko Morishita; Hidesaku Asakura; Akitada Ichinose
Journal:  Int J Hematol       Date:  2018-04-02       Impact factor: 2.319
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.